Welcome to our dedicated page for OS THERAPIES INCORPORATED SEC filings (Ticker: OSTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OS Therapies Incorporated (OSTX) SEC filings page on Stock Titan brings together the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a primary source view of its clinical-stage oncology business. As a NYSE American–listed emerging growth company, OS Therapies uses current reports on Form 8-K, registration statements, and proxy materials to describe its listeria-based cancer immunotherapy programs, ADC and drug conjugate platform, capital structure, and governance decisions.
Investors can use this page to access Form 8-K filings that detail material events such as warrant exercise inducement and exchange offers, gross proceeds from warrant exercises, and the terms of new warrants issued to accredited investors. These filings explain how OS Therapies raises capital to support regulatory submissions and commercial preparation for its lead asset OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma and to fund preparations for the proposed spin-off of its veterinary subsidiary, OS Animal Health.
Other 8-Ks and the company’s definitive proxy statement on Schedule 14A provide insight into corporate governance, including amendments to the certificate of incorporation to increase authorized common stock, changes to the 2023 Incentive Compensation Plan, quorum requirements under the bylaws, and shareholder approvals related to potential share issuances and a shareholder rights agreement. Registration statements on Form S-1 and Form S-3 describe the resale of shares underlying warrants, the company’s status as a smaller reporting company and emerging growth company, and the use of proceeds from warrant exercises.
Through Stock Titan, these filings are updated in near real time from EDGAR and are paired with AI-powered summaries that translate legal and financial language into plain English. Users can quickly understand the key points of complex documents, such as how a warrant inducement affects dilution, what changes a bylaw amendment introduces, or how a registration statement relates to existing warrants. Over time, this filings archive helps investors follow OS Therapies’ progress as it advances OST-HER2 through the regulatory process, develops its tunable ADC (tADC) platform, and executes on planned transactions like the OS Animal Health spin-off.
OS Therapies Incorporated completed a registered direct offering of 2,505,073 shares of common stock, 1,250,893 pre-funded warrants and 3,755,966 common warrants. Investors paid $1.40 per share and common warrant, or $1.399 per pre-funded warrant and common warrant, generating gross proceeds of $5.25 million and net proceeds of approximately $4.7 million.
The company also issued 187,798 placement agent warrants with a $1.54 exercise price. OS Therapies plans to use the cash to fund clinical development, research programs, potential acquisitions, and general corporate purposes, and expects an additional $4 million in non-dilutive VAT and R&D refunds via its U.K. subsidiary.
OS Therapies Incorporated is offering 2,505,073 shares of common stock together with common warrants and, in lieu of some shares, pre-funded warrants to purchase up to 1,250,893 shares, plus common warrants to purchase up to 3,755,966 shares; placement agent warrants to purchase up to 187,798 shares are also included. The combined public offering price for each share and accompanying common warrant is $1.40; pre-funded warrants plus common warrant are priced at $1.399. The offering contemplates up to 5,006,859 shares of common stock underlying pre-funded warrants and common warrants in the aggregate. Net proceeds are estimated at approximately $4.7 million after fees and expenses, and delivery is expected on or about April 2, 2026. The securities are being placed on a best efforts basis by Ceros Financial Services, Inc., and the pre-funded warrants and common warrants will not be listed for trading.
OS Therapies Incorporated filed a prospectus supplement covering the resale of up to 10,529,417 shares of its common stock by certain selling stockholders. The supplement forms part of the company’s previously effective Form S-3 shelf registration statement. An accompanying Form 8-K provides counsel Olshan Frome Wolosky LLP’s legal opinion on the validity of these shares, filed as Exhibit 5.1, along with the related consent.
OS Therapies registered 10,529,417 shares of common stock for resale by selling stockholders pursuant to a prospectus supplement dated March 31, 2026.
The registered shares consist of 2,622,774 shares issuable upon exercise of 2026 Warrants, 1,666,667 shares issuable upon exercise of Bridge Warrants and 6,239,976 shares issuable upon conversion of Bridge Notes. The company will receive no proceeds from resale by selling stockholders; it will receive proceeds only if outstanding warrants are exercised for cash.
OS Therapies Incorporated files its annual report as a clinical-stage biopharmaceutical company focused on Osteosarcoma and other solid tumors. Its lead candidate OST-HER2 showed improved two‑year overall survival versus historical controls and is being advanced toward potential FDA and European regulatory submissions.
The company has raised capital through PIPE, at-the-market, warrant inducement and bridge financings, but has incurred recurring losses, faces substantial doubt about its ability to continue as a going concern, and will need additional funding to complete development, obtain approvals and build commercialization capabilities.
OS Therapies Incorporated entered into a private placement on March 4, 2026, issuing 10.0% original issue discount unsecured convertible promissory notes and accompanying warrants to accredited investors for aggregate gross cash proceeds of $2,000,000.
The notes have an aggregate principal amount of $2,200,000, bear 4% annual interest, and mature on March 4, 2027, with both principal and accrued interest convertible into equity under mandatory and voluntary conversion features, including a 10‑day volume‑weighted price discount mechanism and anti‑dilution adjustments.
Investors also received warrants to purchase up to 1,666,667 common shares at an exercise price of $1.40 per share, based on an average prior trading price of $1.32, with 4.99% or 9.99% ownership caps and a 19.99% overall issuance limit unless stockholders approve more. Net proceeds are earmarked for clinical development, research and development, and general corporate purposes, and the company agreed to restrictive debt covenants, limitations on variable‑price financings, and to register the underlying shares for resale on a Form S‑3 or Form S‑1.
McKean-Dieser Avril Suzette reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Search Theodore F. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Ciccio John reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Acevedo Christopher P. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.